Introduction
The short-term future of oncolytic viral therapy in the United States (US) appears bleak at this time, at least with regard to adenovirus and herpesvirus-based vectors. A small number of adenoviruses (Cell Genesys CG0070, the Rb-mutant Delta-24 adenovirus), vaccinia viruses (Jennerex JX-549) and RNA viruses of several types (e.g. Reolysin, measles) are undergoing clinical trials or will soon enter trials, and may yet prove the promise that excited this field within recent years. However, current interest within pharmaceutical organizations and investment groups is low, making serious clinical development of these agents extremely difficult. In contrast, oncolytic viruses are under active development in China: the first oncolytic virus, H101/ONYX-015, is expected to be approved by the SFDA in 2005, through Sunway Corporation of Shanghai.
Several factors have contributed to the dramatic loss of momentum that this field has witnessed in the US. A major single blow to the adenovirus field came from the tragic death of Mr Jesse Gelsinger in September 1999, while undergoing adenovirus-based gene therapy to treat ornithine transcabamylase deficiency, a rare metabolic disorder. Following this terrible event, experience gained from clinical trials involving adenoviral vectors was evaluated thoroughly by the Recombinant Advisory Committee and local Institutional Regulatory Boards, and clinical research was allowed to proceed. However, there is no doubt that this alarming event had a lasting effect on the field as a whole. In October 2002, it was reported that patients treated for X-linked severe combined immunodeficiency using retroviral transduction of the g-chain of the IL-2 receptor developed a leukemia-like syndrome, triggered by insertional activation of the LMO2 gene, which encodes a transcription factor required for hematopoiesis. While unrelated to oncolytic therapy, this was clearly another blow to technologies relating in any way to gene therapy.
These tragic events clearly added to the risks that have been associated with oncolyic therapy. These perceived risks might have been considered tolerable for patients suffering from terminal cancers, but unfortunately the commercial and clinical upside of this approach has not been sufficient to justify further clinical development in most cases to date. Enthusiasm for oncolytic therapy is currently low among bio-pharmaceutical organizations and investors because of a single major technical limitation: the perceived inability to treat systemic disease (Reid et al., 2002) . This obstacle limits the clinical and commercial value of this platform considerably. In addition, concerns about the cost and technical challenges of manufacturing add to the negative side of the value equation. Finally, clinical responses using local or regional therapy have not been dramatic and have not been subjected to the rigors of randomized clinical testing. They therefore remain anecdotal and therefore not sufficiently compelling to offset the perceived risks and limitations of the approach.
Another major factor has limited enthusiasm for this approach: the current success of small-molecule drugs that target protein kinases and of antibodies that target cancer cell surface proteins. The success of GleVec and the surprising lack of adverse effects associated with compounds with relatively low selectivity have encouraged massive investments in this technology. Furthermore, these drug targets are relatively easy to produce and screen, and medicinal chemistry necessary to optimize compounds and to scale them up for commercial development are well established within the industry, thus reducing many of the risks associated with other approaches. Likewise, the success of antibody-based therapies has maintained focus of resources in this technology in many organizations. Relative to these platforms, oncolytic viral therapy in its firstgeneration state appears risky, with limited upside potential. Reasons to be optimistic
Safety
As discussed in the reviews by Aghi and Martuza (2005) and by Ko et al., (2005) , and in clinical reports published elsewhere, we can conclude that high doses of oncolytic viruses (10 13 particles or higher of adenovirus constructs, e.g.) have proven remarkably safe, with flu-like symptoms as the major consistent side-effect. A conservative approach to dose escalation has been necessary. This is partly because of the alarmingly steep dose-response curves observed in mouse models, in which increases in doses of a few-fold result in acute live failure and death, and, of course, because of the tragic fatality discussed above. In some cases, elevated body temperatures have been of serious concern (Reid et al., 2001) , requiring prolonged hospitalization and careful monitoring, but it is certainly fair to say that these agents have been better tolerated than many cancer therapy protocols. Dosing has often been limited by practical problems associated with producing pure virus at sufficient titers to be effective. Despite these limitations, it appears that a maximum tolerated dose has been approached in several trials, and that particle doses of adenovirus in excess of 10 13 are unlikely to be exceeded with current agents.
On the other hand, the safety profile must be weighed against the therapeutic effects. To date, these have not been sufficiently dramatic to encourage development as single agents. It is conceivable that, if doses could be in increased significantly, this picture could change. However, this would add to the expense of treatment and the problems of manufacturing considerably, and is not likely to be safe using existing vectors, certainly in the case of adenovirus-based systems. Different serotypes or constructs might allow higher doses, but this is not proven. Furthermore, it is not clear to what extent increasing doses would translate into increased efficacy. For example, if efficacy is limited by the fact that only a fraction of cells in tumor express receptors and can be infected, then increasing dosage would not be expected to confer any advantage. Indeed, it is crucial to understand the limitations to this therapeutic approach before we can proceed to the next generation effectively. Replication-competent viruses would not be expected to follow a simple dose-response curve. In theory, a single virus particle has the potential to kill an entire tumor if it replicates and spreads efficiently throughout the tumor mass. Clearly this is not the case, even in nude mouse xenograft models, and a better understanding of the dynamics of viral spread and infection is warranted.
Selectivity
An extraordinary range of concepts have been exploited to generate cancer-selective oncolytic viruses (McCormick, 2001; Nemunaitis and Edelman, 2002) . Viruses developed at ONYX were designed to take advantage of functions missing in cancer cells to confer a cancerspecific host range. ONYX-015 was thought to replicate selectively in cancer cells because these cells lacked functional p53, making the E1B 55K gene unnecessary. While it could be shown that induction of p53 in certain tumor cells restricted ONYX-015 replication, it became clear that tumor selectivity resulted in a novel function of tumor cells: the ability to promote export of viral mRNAs in the absence of E1B 55K (O'Shea et al., 2004) . Other viruses developed at ONYX lacked the capacity to block RB function and can therefore replicate only in RB-deficient cells (Heise et al., 2000; Johnson et al., 2002) . A related virus, delta-24 (with an additional RGD surface modification), will soon enter clinical trials to treat glioblastoma (Fueyo et al., 2003) .
A more general principle takes advantage of tumorselective transcription, as described in detail in Ko et al., (2005) . This approach has led to a series of highly selective agents, with excellent safety profiles, and it is easy to imagine that new and innovative versions of these types of approach will continue to be reported: this is the fertile ground of imaginative molecular biologists and virologists, with a wealth of data from the literature to draw upon, data from the worlds of molecular virology and cancer biology that can be integrated into novel and more potent cancer-selective agents. In this respect, the field of oncolytic viral therapy may have more upside potential than other technology platforms currently under investigation in oncology. For example, there appear to be a small number of enzyme targets that have been well validated and are compelling targets for cancer therapy. Likewise, the number of surface proteins that can be attacked safely and effectively using antibody-based therapy is quite limited. Clearly, new approaches are required to sustain the momentum that has been generated in recent years. These new approaches might include clinical application of RNAi technology, new types of chemistry to attack targets other than kinases, and other creative approaches yet to be described or developed: oncolytic viral therapy may be included on this list in the future.
Potential for further improvements
Oncolytic viral therapy has the potential to destroy a tumor mass of unlimited size, if indeed, productive virus infection spreads from one infected cell to another. However, in experimental systems in which tumors are seeded with infected cells, it has been shown that 5-10% tumor cells need to be infected in order to cause complete tumor destruction. These data strongly imply that infectious virus does not spread efficiently through a tumor mass. This failure may be the main reason that oncolytic viral therapy has not achieved its promise. Other factors must contribute to limited efficacy: for example, clearance of virus from the blood stream by the liver is generally considered a major issue to be circumvented, and, indeed, increased efficiency of delivery to tumor sites would undoubtably increase the potency of existing vectors. This could be achieved by re-targeting or by using viral serotypes that are not cleared efficiently by cells in the liver. The role of the immune system in restricting the efficacy of oncolytic is not yet clear. Responses to local treatment do not appear to be blunted by high levels of circulating neutralizing antibodies generated during repeated treatment, but the efficiency with which this arm of the immune system counteracts virus injected into the blood stream is not yet known: a potent and selective virus could, in principle, destroy a considerable number of tumor cells in the time normally required to mount a strong humoral response. However, a virus that replicates efficiently through a tumor mass should be effective if only a few cells become infected. Future development of this concept should address barriers to the spread of virus through solid tumors and ways of arming viruses to create an increased bystander effect. The latter approach will be of increased importance if viral spread is limited by infiltrating stromal cells, or by tumor cells that express low levels of receptor. A number of attempts to arm replication-competent viruses have already been reported, and summarized elsewhere. These include expression of pro-drug-activating enzymes that facilitate production of chemotoxic compounds in the local tumor environment, cytokines that might elicit a systemic antitumor response and proapoptotic proteins like TNF that might kill local tumor cells directly.
Potential for systemic treatment
In mouse models, oncolytic viruses have proven capable of inducing complete responses after tail-vein injection (Yu et al., 2001) . These encouraging data show that infectious virus particles leak from blood vessels into tumor beds, and replicate with sufficient potency to spread effectively through tumor masses, at least in selected xenograft nude mouse models. In small numbers of clinical trials, replication of ONYX-015 in tumors was observed after IV infusion, though no clinical responses were observed and replication was restricted to small numbers of cells within infected tumors. Three major obstacles need to be overcome before oncolytic viruses are likely to be effective systemically: first, increased potency, as discussed above. Second, the obvious effects of neutralizing antibodies will need to be overcome or avoided. Conceivably, viruses can be infused at sufficient doses to be effective before antibody titers become problematic. More likely, repeat administration will be necessary, and this will lead to high levels of neutralizing antibodies, as described for ONYX-015. Pretreatment with immune-suppressive agents is a possible solution: Reid and co-workers proposed treating patients with Rituxan to prevent neutralizing antibodies being generated in response to ONYX-015. Unfortunately, this approach has not been tested in the clinic. There is good reason to believe that this approach would be safe, since high levels of adenoviruses were well tolerated in patients with low levels of pre-existing antibodies, but the effectiveness of Rituxan in preventing production of neutralizing antibodies remains unknown. Third, it would be desirable to redirect virus particles away from the liver, as proposed elsewhere: this would release virus to attack targeted cancer cells, and could allow administration of higher doses of virus without engendering liver toxicity.
Conclusion
An impressive number of creative approaches have been applied to create viruses that replicate in cancer cells selectively. The feasibility of making such agents is therefore now well accepted. However, several barriers stand in the way of developing this platform into the mainstream of modern oncology practice. Lack of efficacy at tolerable levels is the most obvious shortfall, and may be attributed to poor replication within solid tumor masses, poor access of infused or injected virus into tumors, loss of virus through liver clearance and effects of neutralizing antibodies. Each of these problems has a potential solution, and it seems likely that continued efforts to develop this platform, primarily in academic medical centers, will gradually address each issue, and that these efforts, if successful, will pave the way for new attempts to develop oncolytic viruses in the private sector. Currently, there is no new technology platform on the horizon that has more potential, and the need for such revolutionary approaches is only underscored by the modest effects of alternative targeted therapies on solid tumors reported so far. The clinical need has not diminished, and should drive further development of oncolytic viral therapies in the near future.
